Icosavax raises $51M to take VLP RSV vaccine into humans

Icosavax has raised a $51 million series A round to take respiratory syncytial virus (RSV) vaccine IVX-121 through phase 1b in older adults. The vaccine is built on computationally designed self-assembling viruslike particle (VLP) technology Icosavax thinks can eliminate some of the barriers to protecting people against RSV.